Advertisement
September 2021

September 2021

In this issue, our cover features looks at the mRNA field – asking what lies ahead for mRNA post-pandemic, featuring contributions from CureVac, Sartorius, and more. We also speak with the Drugs for Neglected Diseases initiative to learn about a partnership that brought a new hep C treatment to Malaysia. In In My View, we cover advanced therapies, rapid-dissolve tablet technologies, and the pharma supply chain. We also sit down with Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA.

Recent Issues
Advertisement